ORGANIZATION

Market Price Survey for Off-Year Revision Should “Cover All Products”: JPWA

May 15, 2017
Executives from the Federation of Japan Pharmaceutical Wholesalers Association (JPWA) on May 11 called for a market price survey covering all products for the sake of “off-year” NHI price revisions, or revisions in years between the current regular biennial revisions,…

To read the full story

Related Article

ORGANIZATION

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Hayate Horiguchi

Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…

By Philip Carrigan

We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…